XOMA Royalty Corp
Undisclosed program
Resolved
7days ago
Phase 1 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 1 trial results for Undisclosed program in its lead indication are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Key 2026 pipeline events : • Phase 2b data from volixibat in PSC in Q2 and Phase 3 data from ersodetug in tumor HI in 2H”